Simcere Pharmaceutical Group (SCR) Misses Q2 EPS by 2c

Simcere Pharmaceutical Group (NYSE: SCR) reported Q2 EPS of $0.08, $0.02 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $83.2 million versus the consensus estimate of $86.83 million.

For earnings history and earnings-related data on Simcere Pharmaceutical Group (SCR) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
• Alphabet stock soars 12% to record high on Q1 earnings beat, first-ever dividend
• USCB Financial Holdings, Inc. (USCB) Tops Q1 EPS by 2c